110 related articles for article (PubMed ID: 10917540)
1. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.
Maisey NR; Webb A; Flux GD; Padhani A; Cunningham DC; Ott RJ; Norman A
Br J Cancer; 2000 Aug; 83(3):287-93. PubMed ID: 10917540
[TBL] [Abstract][Full Text] [Related]
2. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
3. Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer.
Yoshioka M; Sato T; Furuya T; Shibata S; Andoh H; Asanuma Y; Hatazawa J; Shimosegawa E; Koyama K; Yamamoto Y
J Gastroenterol; 2004 Jan; 39(1):50-5. PubMed ID: 14767734
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Lee DH; Kim SK; Lee HY; Lee SY; Park SH; Kim HY; Kang KW; Han JY; Kim HT; Lee JS
J Thorac Oncol; 2009 Jul; 4(7):816-21. PubMed ID: 19487962
[TBL] [Abstract][Full Text] [Related]
5. Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers.
Kuwatani M; Kawakami H; Eto K; Haba S; Shiga T; Tamaki N; Asaka M
Intern Med; 2009; 48(11):867-75. PubMed ID: 19483354
[TBL] [Abstract][Full Text] [Related]
6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
7. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
8. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic evaluation and prognostic value of interim hybrid PET/CT with (18)F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma.
Zhao J; Qiao W; Wang C; Wang T; Xing Y
Hematology; 2007 Oct; 12(5):423-30. PubMed ID: 17852456
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial.
Ott K; Fink U; Becker K; Stahl A; Dittler HJ; Busch R; Stein H; Lordick F; Link T; Schwaiger M; Siewert JR; Weber WA
J Clin Oncol; 2003 Dec; 21(24):4604-10. PubMed ID: 14673049
[TBL] [Abstract][Full Text] [Related]
11. Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?
Price P
Br J Cancer; 2000 Aug; 83(3):281-3. PubMed ID: 10917538
[No Abstract] [Full Text] [Related]
12. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Francis RJ; Byrne MJ; van der Schaaf AA; Boucek JA; Nowak AK; Phillips M; Price R; Patrikeos AP; Musk AW; Millward MJ
J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
[TBL] [Abstract][Full Text] [Related]
14. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
15. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
Bender H; Bangard N; Metten N; Bangard M; Mezger J; Schomburg A; Biersack HJ
Hybridoma; 1999 Feb; 18(1):87-91. PubMed ID: 10211794
[TBL] [Abstract][Full Text] [Related]
16. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
17. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer.
Couper GW; McAteer D; Wallis F; Norton M; Welch A; Nicolson M; Park KG
Br J Surg; 1998 Oct; 85(10):1403-6. PubMed ID: 9782025
[TBL] [Abstract][Full Text] [Related]
18. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
19. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
20. Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cells.
Ruf J; Amthauer H; Oettle H; Steinmüller T; Plotkin M; Pelzer U; Scholman HJ; Felix R; Wust P
Onkologie; 2004 Jun; 27(3):287-90. PubMed ID: 15249719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
